New targeted treatments for non-Hodgkin lymphoma
Official title: Precision next-generation radioimmunotherapies to Cure Non-Hodgkin Lymphoma
Funded at Washington University · NIH-11050386 · Data updated 2026-11-12
This study is working on new treatments for non-Hodgkin lymphoma using advanced antibodies that could be more effective and safer, with the hope of offering better options for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | December 5, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $641,534 |
| NIH project number | 1R01CA289487-01A1 |
| Project ID | NIH-11050386 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with non-Hodgkin lymphoma who have not responded adequately to existing therapies.
✕Less likely to help
Patients with other types of cancers or those who do not have non-Hodgkin lymphoma may not receive any benefit from this research.
What this research studies
This research focuses on developing advanced radioimmunotherapies specifically designed to treat non-Hodgkin lymphoma (NHL). By utilizing next-generation fully-human anti-CD20 antibodies, the research aims to create more effective and precise treatment options that can potentially lead to cures. The approach involves evaluating these novel therapies in preclinical models to ensure their safety and efficacy before moving to clinical trials. Patients may benefit from these innovative treatments that address the limitations of existing therapies.
Why it matters
Potential benefit: If successful, this research could provide more effective and targeted treatment options for patients with non-Hodgkin lymphoma.
How similar studies have gone: Previous research has shown promise with first-generation radioimmunotherapies, indicating potential for success with these next-generation approaches.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Wahl, Richard Leo — Washington University
- Study coordinator: Wahl, Richard Leo
Related research
Other NIH-funded projects on the same topics.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma
Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.
-
AI-designed drugs targeting a common lymphoma mutation (MYD88 L265P)
Researchers are using artificial intelligence to create and test new drugs that block a common MYD88 mutation found in many B‑cell non‑Hodgkin lymphomas to help people with these cancers.
-
New combination therapy for non-Hodgkin lymphoma
A virus-based combination treatment aims to boost the immune system to help people and companion dogs with relapsed or treatment-resistant diffuse large B-cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.